CHF 42.54 intraday drop Feb 2026: BMY.SW Bristol-Myers Squibb (SIX) bounce
The stock opened at CHF 42.54 and trades down -4.40% intraday on 23 Feb 2026, putting BMY.SW stock in an oversold setup we are watching for a short rebound. Volume is 500.00 shares versus an average of 22.00 shares, giving a relative volume of 22.73 and signalling a sharp intraday reaction. Fundamentals remain mixed: EPS is 2.66 and reported PE is 15.99, while the healthcare sector shows modest 3-month strength. Meyka AI, as an AI-powered market analysis platform, flags the move as an oversold bounce candidate but stresses careful risk control.
Intraday technicals: BMY.SW stock setup
Price sits at CHF 42.54 with day high and low equal, indicating a rapid gap lower. MACD is negative at -0.11 with a histogram of -0.07, and the Keltner lower band is 42.59, placing the price marginally below a key volatility band. Relative volume of 22.73 shows outsized selling versus the 22.00 average, heightening short-term mean-reversion odds.
ADX is reported at 100.00, signalling a strong trend; in oversold-bounce trades that warns of continuation risk. Traders should watch intraday support at the year low CHF 42.54 and resistance at the 50-day average CHF 43.75 for a first bounce target.
Catalysts and news flow impacting BMY.SW stock
No company-specific release intraday explains the drop; the next earnings date is 30 Apr 2026. Broader sector moves and market re-rating in healthcare likely contributed to pressure. For background on index and market signals see the recent lists at Investing.com US 500 components and market commentary at MarketBeat.
Monitor pipeline updates, regulatory headlines, and any trading notices on SIX, since news catalysts can turn an oversold bounce into a sustained reversal or a failed bounce.
Meyka grade and model forecast for BMY.SW stock
Meyka AI rates BMY.SW with a score out of 100: 73.41 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score highlights solid cash flow metrics but elevated leverage.
Meyka AI’s forecast model projects a 1-year price of CHF 39.34, implying a downside of -7.53% versus the current CHF 42.54. Forecasts are model-based projections and not guarantees. Use this alongside technical bounce targets for a balanced view.
Valuation and balance sheet snapshot
Current market cap is CHF 70,703,584,454.00, EPS is 2.66, and the full-quote PE reads 15.99, below many high-growth peers. Price-to-sales is roughly 1.31 and price-to-book near 4.54, reflecting premium pricing versus book value. Debt to equity is high at 3.45, and net-debt-to-EBITDA is approximately 3.00, making leverage the main structural risk.
Dividend yield sits near 3.50%, with a payout ratio of 72.54%, so income investors must weigh payout sustainability against leverage and free cash flow conversion.
Risk-reward and sector context
Healthcare sector 3-month performance is +10.78%, so BMY.SW underperformance today contrasts with sector strength. Key upside drivers: portfolio drugs like Eliquis and oncology assets and steady free cash flow yield 23.33% (free cash flow yield TTM). Key risks: elevated debt ratios, surgical regulatory outcomes, and potential pipeline setbacks.
For an oversold-bounce strategy, risk controls should cap position size and use tight intraday stops given ADX 100.00 suggests trend continuation risk.
Trading plan and price targets for the oversold bounce
Short-term bounce target: CHF 43.75 (50-day average). Near-term resistance: CHF 44.75 (year high). A conservative recovery target for traders is CHF 46.00 if momentum returns with volume.
Entry idea for active traders: consider partial exposure on a strong intraday reversal candle above CHF 43.00 with volume above 1,000.00 (relative increase) and a stop below CHF 42.00. Adjust sizing for leverage and the elevated debt profile.
Final Thoughts
BMY.SW stock sits at CHF 42.54 after a -4.40% intraday move that meets classic oversold-bounce criteria: sharp relative volume (22.73) and price hugging the lower Keltner band (42.59) near the day low. Technicals favour a short, tactical rebound to the 50-day average at CHF 43.75 and resistance at CHF 44.75, but ADX at 100.00 warns traders that trend continuation is possible. Meyka AI’s model projects CHF 39.34, implying -7.53% versus the current price; this highlights the difference between a tactical bounce and a longer-term re-rating. Our view: short-term traders can look for a disciplined intraday entry above CHF 43.00 with tight stops. Longer-term investors should weigh the B+ (BUY) grade from Meyka AI against high leverage and the model downside before adding exposure. Remember forecasts are model-based projections and not guarantees; manage risk and confirm any rebound with rising volume and positive sector cues. For live quotes and order placement use the BMY.SW page on Meyka AI for real-time tools and signals.
FAQs
Is BMY.SW stock a buy after the intraday drop?
BMY.SW stock shows a tactical oversold bounce setup, but Meyka AI flags leverage and model downside to CHF 39.34. Short-term traders may buy with tight stops; long-term buyers should wait for clearer recovery and improving leverage metrics.
What are realistic short-term targets for BMY.SW stock?
Short-term targets: CHF 43.75 (50-day average) and CHF 44.75 (year high). A sustained move above CHF 46.00 would signal deeper recovery for BMY.SW stock.
How does Meyka AI assess BMY.SW stock risk?
Meyka AI rates BMY.SW with leverage and net-debt-to-EBITDA near 3.00 as main risks. The grade B+ (BUY) balances strong cash flow versus high debt, so risk management is essential.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.